QCG
LAB icon

Quadrant Capital Group’s Standard BioTools LAB Stock Holding History

Quadrant Capital Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,014
Closed -$8K – 2036
2016
Q3 		$8K Hold
1,014
– – 0.01% 1120
2016
Q2 		$9K Buy
+1,014
New +$9.53K 0.01% 1046

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Quadrant Capital Group's LAB Position: Q4 2016 in Review

Quadrant Capital Group sold out of Standard BioTools (LAB) in Q4 2016, closing a stake of 1,014 shares — an estimated $8K sold.

Quadrant Capital Group first reported a position in LAB in Q2 2016 and held it in 2 quarters. The position peaked at $9K in Q2 2016. 83 funds tracked by Wall St. Rank hold LAB as of Q4 2016.

  • Quadrant Capital Group reported no remaining Standard BioTools position as of Q4 2016 after selling out during the quarter.
  • Quadrant Capital Group sold 1,014 Standard BioTools shares in Q4 2016, an estimated $8K.
  • Quadrant Capital Group first reported a position in Standard BioTools in Q2 2016 and held it in 2 quarters.
  • Quadrant Capital Group's Standard BioTools position peaked at $9K in Q2 2016.
  • 83 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2016.

Based on Quadrant Capital Group's 13F filing for Q4 2016, filed 11 Jan 2017.